Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McGill University

$105,000.00

The Hepatitis C Revolution: Evaluating the Impact of Direct Acting Antiviral Therapy in a HIV-Hepatitis C Co-Infected Population

FY 2016-17

Summary
The Hepatitis C virus (HCV) causes serious liver damage, that can lead to premature death. This process is accelerated considerably among people co-infected with both HIV and HCV. To reduce the growing clinical and healthcare burden of advanced liver disease, this population needs to be treated and cured of Hepatitis C. Fortunately, cures for Hepatitis C now exist, however at an extraordinary cost, up to $120,000/treatment. Clinical trial results show these drugs are well tolerated and cure most people of HCV. However clinical trials do not always reflect what happens in the "real world". My doctoral thesis, will evaluate the "real world" health and economic impacts of treating HIV-Hepatitis C co-infected individuals with these new treatments. I will use a large cohort of participants, representing approximately a quarter of the total co-infected population in care in Canada. Details on demographic, risk, treatment and clinical data have been and will continue to be collected for the next 5 years. By 2017 I expect close to 400 people in this cohort will have received Hepatitis C treatment. Based on this data I will: (1) Describe the need for "real world" data; (2) Evaluate the different provincial policies regarding Hepatitis C therapy across Canada; and describe who initiates therapy by various risk profiles (People who inject drugs, people of Aboriginal decent, Women, and Men who has Sex with Men); (3) Estimate, short and long term health and economic impacts of treatment. When using observational data oppose to clinical trial data, being able to identify an unbiased result requires a comprehensive understanding of epidemiology. This is why I will explore different epidemiological methods to estimate the impact of these new drugs. Although cures are now available, due to the costs access to treatment is limited. I hope the results from my thesis will improve clinical care and avoid health inequalities in this vulnerable population.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
365442
Name
Saeed Sahar Z
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Doctoral Research Awards - B
Projecttitle
The Hepatitis C Revolution: Evaluating the Impact of Direct Acting Antiviral Therapy in a HIV-Hepatitis C Co-Infected Population
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Econometric Methods; Epidemiology; Health Outcomes; Health Services; Hepatitis C; Hepatitis C Treatments; Hiv; Instrumental Variables; Natural Experiments; Propensity Scores
Abstract
The Hepatitis C virus (HCV) causes serious liver damage, that can lead to premature death. This process is accelerated considerably among people co-infected with both HIV and HCV. To reduce the growing clinical and healthcare burden of advanced liver disease, this population needs to be treated and cured of Hepatitis C. Fortunately, cures for Hepatitis C now exist, however at an extraordinary cost, up to $120,000/treatment. Clinical trial results show these drugs are well tolerated and cure most people of HCV. However clinical trials do not always reflect what happens in the "real world". My doctoral thesis, will evaluate the "real world" health and economic impacts of treating HIV-Hepatitis C co-infected individuals with these new treatments. I will use a large cohort of participants, representing approximately a quarter of the total co-infected population in care in Canada. Details on demographic, risk, treatment and clinical data have been and will continue to be collected for the next 5 years. By 2017 I expect close to 400 people in this cohort will have received Hepatitis C treatment. Based on this data I will: (1) Describe the need for "real world" data; (2) Evaluate the different provincial policies regarding Hepatitis C therapy across Canada; and describe who initiates therapy by various risk profiles (People who inject drugs, people of Aboriginal decent, Women, and Men who has Sex with Men); (3) Estimate, short and long term health and economic impacts of treatment. When using observational data oppose to clinical trial data, being able to identify an unbiased result requires a comprehensive understanding of epidemiology. This is why I will explore different epidemiological methods to estimate the impact of these new drugs. Although cures are now available, due to the costs access to treatment is limited. I hope the results from my thesis will improve clinical care and avoid health inequalities in this vulnerable population.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Saeed, Sahar Z
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McGill University - $105,000 Grant (2016-17) | Canada Spends